RU2641903C2 - Новые производные салициловой кислоты, их фармацевтически приемлемая соль, композиции и способ применения - Google Patents

Новые производные салициловой кислоты, их фармацевтически приемлемая соль, композиции и способ применения Download PDF

Info

Publication number
RU2641903C2
RU2641903C2 RU2014152697A RU2014152697A RU2641903C2 RU 2641903 C2 RU2641903 C2 RU 2641903C2 RU 2014152697 A RU2014152697 A RU 2014152697A RU 2014152697 A RU2014152697 A RU 2014152697A RU 2641903 C2 RU2641903 C2 RU 2641903C2
Authority
RU
Russia
Prior art keywords
compound
cancer
stat3
mhz
cdcl
Prior art date
Application number
RU2014152697A
Other languages
English (en)
Russian (ru)
Other versions
RU2014152697A (ru
Inventor
Патрик Томас ГАННИНГ
Сайна ХЭФТЧЕНЕРИ
Брент Дэвид Джордж ПЕЙДЖ
Сэмьюэль ВАЙСС
Хема Арти ЛАЧМЭН
Мелисса Л. ФИШЕЛ
Original Assignee
Дзе Гавернинг Каунсил Оф Дзе Юниверсити Оф Торонто
Ютиай Лимитед Партнершип
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Гавернинг Каунсил Оф Дзе Юниверсити Оф Торонто, Ютиай Лимитед Партнершип, Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн filed Critical Дзе Гавернинг Каунсил Оф Дзе Юниверсити Оф Торонто
Publication of RU2014152697A publication Critical patent/RU2014152697A/ru
Application granted granted Critical
Publication of RU2641903C2 publication Critical patent/RU2641903C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3882—Arylalkanephosphonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
RU2014152697A 2012-05-25 2013-05-24 Новые производные салициловой кислоты, их фармацевтически приемлемая соль, композиции и способ применения RU2641903C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261651757P 2012-05-25 2012-05-25
US61/651,757 2012-05-25
PCT/US2013/042689 WO2013177534A2 (en) 2012-05-25 2013-05-24 New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof

Publications (2)

Publication Number Publication Date
RU2014152697A RU2014152697A (ru) 2016-07-20
RU2641903C2 true RU2641903C2 (ru) 2018-01-23

Family

ID=49624538

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014152697A RU2641903C2 (ru) 2012-05-25 2013-05-24 Новые производные салициловой кислоты, их фармацевтически приемлемая соль, композиции и способ применения

Country Status (9)

Country Link
US (3) US9650399B2 (enExample)
EP (1) EP2854819B1 (enExample)
JP (2) JP6290871B2 (enExample)
CN (2) CN110003104A (enExample)
BR (1) BR112014029439A2 (enExample)
CA (1) CA2874057A1 (enExample)
HK (1) HK1218709A1 (enExample)
RU (1) RU2641903C2 (enExample)
WO (1) WO2013177534A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6570512B2 (ja) * 2013-03-22 2019-09-04 ユニバーシティ・オブ・ハワイＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｈａｗａｉｉ 新規なＳｔａｔ３阻害剤
WO2015179956A1 (en) * 2014-05-30 2015-12-03 The Governing Council Of The University Of Toronto Sulfonamide compounds and their use as stat5 inhibitors
EP3570836A4 (en) * 2017-01-23 2020-08-19 The University of Hawaii 2-ARYLSULFONAMIDO-N-ARYLACETAMIDE STAT3 INHIBITORS
CN113661158A (zh) * 2018-12-21 2021-11-16 多伦多大学管理委员会 新型水杨酸衍生物、其药学上可接受的盐、其组合物及其使用方法
KR102980990B1 (ko) 2019-04-05 2026-06-25 카이메라 쎄라퓨틱스 인코포레이티드 Stat 분해제 및 이의 용도
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
CN115551496A (zh) * 2020-03-05 2022-12-30 詹皮克斯有限公司 Stat抑制性化合物和组合物
JP2023515236A (ja) * 2020-03-05 2023-04-12 ジャンピックス，エルティーディ． α置換されたＳＴＡＴ阻害剤およびその組成物
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
CN112941036B (zh) * 2021-02-08 2023-06-09 吉林惠康生物药业有限公司 一种提高狂犬病毒在人二倍体细胞中复制水平的方法
CN114751927B (zh) * 2022-03-08 2023-10-31 中山大学 一种硼酸化合物、制备方法及用途
CN118994047B (zh) * 2024-08-13 2026-02-10 中国药科大学 一种水杨醛衍生物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117438A2 (en) * 2009-04-06 2010-10-14 University Of Central Florida Research Foundation, Inc. Compounds that suppress cancer cells and exhibit antitumor activity
RU2009116653A (ru) * 2006-10-02 2010-11-10 Оцука Фармасьютикал Ко., Лтд. (Jp) Ингибитор активации stat3/5
WO2012018868A1 (en) * 2010-08-02 2012-02-09 University Of Central Florida Research Foundation, Inc. Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of stat proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2487156B1 (en) * 2003-12-11 2014-07-16 Board Of Regents The University Of Texas System Compounds for treatment of cell proliferative diseases
WO2007115269A2 (en) * 2006-03-31 2007-10-11 The Board Of Regents Of The University Of Texas System Orally bioavailable caffeic acid related anticancer drugs
WO2007136858A2 (en) 2006-05-19 2007-11-29 H. Lee Moffitt Cancer Center & Research Institute Small molecule inhibitors of stat3 with anti-tumor activity
NZ590355A (en) * 2008-07-10 2013-01-25 Yakult Honsha Kk Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
JP6570512B2 (ja) * 2013-03-22 2019-09-04 ユニバーシティ・オブ・ハワイＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｈａｗａｉｉ 新規なＳｔａｔ３阻害剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2009116653A (ru) * 2006-10-02 2010-11-10 Оцука Фармасьютикал Ко., Лтд. (Jp) Ингибитор активации stat3/5
WO2010117438A2 (en) * 2009-04-06 2010-10-14 University Of Central Florida Research Foundation, Inc. Compounds that suppress cancer cells and exhibit antitumor activity
WO2012018868A1 (en) * 2010-08-02 2012-02-09 University Of Central Florida Research Foundation, Inc. Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of stat proteins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
B.D.G. PAGE ET AL., Identification of a non-phosphorylated, cell permeable, small molecule ligand for the STAT3 SH2 domain, BIOORG. MED. CHEM. LETT., 2011, Vol. 21, pp. 5605-5609. *
B.D.G. PAGE ET AL., Small Molecule STAT5-SH2 Domain Inhibitors Exhibit Potent Antileukemia Activity, J. MED. CHEM., 2011, Vol. 55, pp. 1047-1055. *
B.D.G. PAGE ET AL., Small Molecule STAT5-SH2 Domain Inhibitors Exhibit Potent Antileukemia Activity, J. MED. CHEM., 2011, Vol. 55, pp. 1047-1055. B.D.G. PAGE ET AL., Identification of a non-phosphorylated, cell permeable, small molecule ligand for the STAT3 SH2 domain, BIOORG. MED. CHEM. LETT., 2011, Vol. 21, pp. 5605-5609. S. FLETCHER ET AL., Antagonism of the STAT3-STAT-3 Protein Dimer with Salicylic Acid Based Small Molecules, CHEM. MED. CHEM., 2011, 6, pp. 1459-1470. *
S. FLETCHER ET AL., Antagonism of the STAT3-STAT-3 Protein Dimer with Salicylic Acid Based Small Molecules, CHEM. MED. CHEM., 2011, 6, pp. 1459-1470. *
S. FLETCHER ET AL., Disruption of Transcriptionally Active STAT3 Dimers with Non-phosphorylated, Salicylic Acid-Based Small Molecules: Potent in vitro and Tumor Cell Activities, CHEM. BIO. CHEM., 2009, Vol. 10, pp. 1959-1964. *

Also Published As

Publication number Publication date
JP6290871B2 (ja) 2018-03-07
EP2854819B1 (en) 2020-01-15
CN105120854B (zh) 2019-04-09
BR112014029439A2 (pt) 2017-06-27
EP2854819A4 (en) 2016-06-15
RU2014152697A (ru) 2016-07-20
US20190382422A1 (en) 2019-12-19
HK1218709A1 (zh) 2017-03-10
CN110003104A (zh) 2019-07-12
US20150158894A1 (en) 2015-06-11
JP2018109017A (ja) 2018-07-12
CN105120854A (zh) 2015-12-02
WO2013177534A2 (en) 2013-11-28
US20170267704A1 (en) 2017-09-21
WO2013177534A3 (en) 2015-05-28
EP2854819A2 (en) 2015-04-08
JP6543366B2 (ja) 2019-07-10
CA2874057A1 (en) 2013-11-28
US9650399B2 (en) 2017-05-16
US10377780B2 (en) 2019-08-13
JP2015522551A (ja) 2015-08-06

Similar Documents

Publication Publication Date Title
JP6543366B2 (ja) 新しいサリチル酸誘導体、薬学上許容可能なその塩、その組成物及びその使用方法
CN105142634B (zh) 包含Src同源-2结构域的致癌性蛋白酪氨酸磷酸酶-2(SHP2)的基于羟基吲哚羧酸的抑制剂
US10954258B2 (en) STAT3 dimerization inhibitors
CN103547152A (zh) 溴结构域蛋白的抑制剂作为基因表达的调节剂
BR112012002511B1 (pt) Compostos análogos de aril esfingosina 1-fosfato bicíclica, e sua composição farmacêutica
WO2006024837A1 (en) Isoindolin-1-one derivatives
WO2007136858A2 (en) Small molecule inhibitors of stat3 with anti-tumor activity
RU2707094C2 (ru) Соединения сульфонамида и их применение в качестве ингибиторов stat5
CN108409663A (zh) 微管抑制剂及其制备方法和用途
US20220089531A1 (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
JP2019510755A (ja) ２，３−エポキシスクシニル誘導体、その調製方法及び使用
US8586749B2 (en) Compounds that suppress cancer cells and exhibit antitumor activity
WO2018189679A1 (en) Isoindoline derivatives for use as ampk activators
RU2285521C2 (ru) ИНГИБИТОРЫ ФОСФАТАЗ cdc25
WO2021143923A1 (zh) 硼酸衍生物
EP3039014A1 (en) Substituted naphthalene compounds as calcium sensing receptor modulators
Pokhvisneva et al. Reaction of arylsulfonyl chlorides with 1-methoxy-3-methyltriaz-1-ene 2-oxide sodium salt
HK40063807A (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
Paolini et al. Preparation of isoindoline derivatives for use as AMPK activators

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200525